REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 350 participants.

Also called NCT07834372

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 350 participants (planned count) (from the registry)
Sponsor
  • Avania Registry lists this organization as a collaborator
  • HeartFlow, Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07834372
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07834372. Randomized; no masking; primary purpose prevention. Start 2026-10 (anticipated); primary completion 2027-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease
Acronym
REWRITE-CAD
Intervention (Device)
Heartflow Analysis
Lead sponsor
HeartFlow, Inc. (class: industry)
Collaborator
Avania (class: industry)

Record details

Record id
cardio:ct-nct07834372
Content hash
ce4f77cf56b6c531678bf23bc037a77e32735ebdaa3618484927b731d4e671b8